The translational challenge in Chagas disease drug development

作者：Jadel Muller Kratz, Karolina Ribeiro Gonçalves, Lavínia Maria Dal’Mas Romera, Carolina Borsoi Moraes, Paula Rego Bittencourt-Cunha, Sérgio Schenkman, Eric Chatelain, Sergio Sosa‐Estáni · 发表于：Memórias do Instituto Oswaldo Cruz · 年份：2022 · DOI：10.1590/0074-02760200501 · 被引用次数：61 · 研究领域：Trypanosoma species research and implications、Research on Leishmaniasis Studies、Synthesis and Biological Evaluation

Chagas disease is a neglected tropical disease caused by the protozoan parasite Trypanosoma cruzi. There is an urgent need for safe, effective, and accessible new treatments since the currently approved drugs have serious limitations. Drug development for Chagas disease has historically been hampered by the complexity of the disease, critical knowledge gaps, and lack of coordinated R&D efforts. This review covers some of the translational challenges associated with the progression of new chemical entities from preclinical to clinical phases of development, and discusses how recent technological advances might allow the research community to answer key questions relevant to the disease and to overcome hurdles in R&D for Chagas disease.